Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. Specifically, the stock is overvalued on EV/EBITDA.
Target Price
The average target price of GBIO is 5.3 and suggests 1% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decre